AbCellera Biologics Inc 8-K, filed Jul 6, 2022
AbCellera Biologics Inc. (ABCL)
About this 8-K
AbCellera Biologics Inc filed this 8-K on July 6, 2022, reporting on events of June 29, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
|
|
|
|
|
|
||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________________
FORM
__________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
__________________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________________
|
|
|
|
|
Not Applicable |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
|
|
|
|
|
|
|
(Address of registrant’s principal executive office) |
|
|
|
(Zip code) |
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
|
|
||
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective June 29, 2022, Neil Berkley is no longer the Chief Business Officer of AbCellera Biologics Inc. (the “Company”). Mr. Berkley’s departure was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.
As a named executive officer of the Company, Mr. Berkley is entitled to certain benefits under the Company’s Executive Severance Plan, the material terms of which were disclosed under “Executive Compensation” in the Company’s definitive proxy statement for its 2022 annual meeting of stockholders filed with the SEC on April 28, 2022.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: July 6, 2022 |
ABCELLERA BIOLOGICS INC. |
||||||||||
|
|
|
|
|||||||||
|
|
By: |
|
/s/ Carl L. G. Hansen |
||||||||
|
|
|
|
Carl L. G. Hansen, Ph.D. |
||||||||
|
|
|
|
Chief Executive Officer and Director (Principal Executive Officer) |
||||||||